All In Biotech

Drug Trial Radar · NCT00509106

Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia

A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Ceftriaxone in the Treatment of Adult Subjects With Community-Acquired Pneumonia

Last checked: Nov 19, 2026Latest source record: Mar 14, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 622 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

622

Actual

Start

Jul 2007

Primary completion

Aug 2008

Study completion Jun 2009

Sponsor

Lead sponsor
Forest LaboratoriesAbbVie (ABBV)
Sponsor type
Industry
First posted
Jul 31, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to determine if the antibiotic ceftaroline is safe and effective in the treatment of community-acquired pneumonia in adults.

Conditions

  • Bacterial Pneumonia

Interventions

  • Ceftaroline fosamil for InjectionDrug

    2 consecutive, 300 mg dose parenteral infused over 30 minutes, every 12 hours for 5 to 7 days

  • CeftriaxoneDrug

    1 g dose parenteral infused over 30 minutes, every 24 hours for 5 to 7 days

  • PlaceboDrug

    Subjects randomized to receive ceftriaxone will receive ceftriaxone at a dose of 1 g infused over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h). Twelve hours after each dose of ceftriaxone and saline placebo (ie, between ceftriaxone doses), subjects in this group will receive two consecutive saline placebo infusions, each infused over 30 minutes q24h. The ceftriaxone and saline placebo infusions will correspond to the q12h infusions of ceftaroline, thereby maintaining the blind

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Cure Rate for Ceftaroline Compared to That for Ceftriaxone at the Test of Cure (TOC) in the Modified Intent to Treat Efficacy (MITTE) PopulationTime frame: 8-15 days after last dose of study drug
  2. Clinical Cure Rate for Ceftaroline Compared With That for Ceftriaxone at TOC in the Clinically Evaluable (CE) PopulationTime frame: 8-15 days after last dose of study drug

Locations

134 sites in 15 countries. Site status is shown where the registry gives one.

  • Investigational Site

    Durham, North Carolina

  • Investigational Site

    Buenos Aires, Argentina

  • Investigational Site

    Buenos Aires, Argentina

  • Investigational Site

    Buenos Aires, Argentina

  • Investigational Site

    Buenos Aires, Argentina

  • Investigational Site

    Buenos Aires, Argentina

  • Investigational Site

    Buenos Aires, Argentina

  • Investigational Site

    Buenos Aires, Argentina

  • Investigational Site

    Buenos Aires, Argentina

  • Invetigational Site

    Buenos Aires, Argentina

  • Investigational Site

    Córdoba, Argentina

  • Investigational Site

    Córdoba, Argentina

  • INvestigational Site

    Córdoba, Argentina

  • Investigational Site

    Córdoba, Argentina

  • Investigational Site

    Entre Ríos, Argentina

  • Investigational Site

    Granadero Baiggoria, Argentina

  • Investigational Site

    Paraná, Argentina

  • Investigational Site

    Santa Fe, Argentina

  • Investigational Site

    Santa Fe, Argentina

  • Investigational Site

    Autonoma, Buenos Aires, Argentina

  • Investigational Site

    Mar del Plata, Buenos Aires, Argentina

  • Investigational Site

    Merlo, Buenos Aires, Argentina

  • Investigational Site

    Córdoba, Córdoba Province, Argentina

  • Investigational Site

    Steyr, Austria

  • Investigational Site

    Vienna, Austria

  • Investigational Site

    Wels, Austria

  • Investigational site

    Grieskirchner, Wels, Austria

  • Investigational Site

    Plovdiv, Bulgaria

  • Investigational Site

    Rousse, Bulgaria

  • Investigational Site

    Sofia, Bulgaria

  • Investigational Site

    Sofia, Bulgaria

  • Investigational Site

    Sofia, Bulgaria

  • Investigational Site

    Sofia, Bulgaria

  • Investigational Drug

    Varna, Bulgaria

  • Investigational Site

    Santiago, Chile

  • Investigational Site

    Santiago, Chile

  • Investigational Site

    Santiago, Chile

  • Investigational Site

    Talcahuano, Chile

  • Investigational Site

    Temuco, Chile

  • Inestigational Site

    Valdivia, Chile

Showing 40 of 134 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.